Halozyme remains a 'Hold' due to uncertainty about post-ENHANZE growth after core U.S. patent expiration in 2027. HALO's Q2 results were strong, with 41% revenue growth and high-margin royalties from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback